Showing 1 - 7 of 7
Using the overcharge estimates for 395 cartel episodes, we evaluate the impact of cartel characteristics on the size of overcharges imposed by cartels in different geographic markets and during six antitrust law regimes starting from the 18th century. We find that the average overcharge imposed...
Persistent link: https://www.econbiz.de/10012750256
Using a sample of modern international cartels, we analyze the level and determinants of cartel sanctions imposed on the participants of these cartels in a number of antitrust jurisdictions. There is empirical evidence suggesting that gains from collusive conduct outweigh its costs represented...
Persistent link: https://www.econbiz.de/10012724686
This article examines the nature of the effect of the U.S. Supreme Court's Empagran decision through the lens of the global vitamins cartel, using legal and economic analysis and also empirical data to describe the effect. The article commences with a discussion of the analytic approach adopted...
Persistent link: https://www.econbiz.de/10014051606
Using the overcharge estimates for 333 cartel episodes, we evaluate the impact of cartel characteristics and changes in the market and legal environment on the magnitude of overcharges imposed by private cartels in the US and other geographic markets as early as the 18th century. The median...
Persistent link: https://www.econbiz.de/10012766577
This three-page article is a succinct, nontechnical introduction to the topic of the economics private international cartels. It explains contemporary economic theories of collusion, the major empirical features of discovered cartels, antitrust laws meant to combat price fixing, and the concept...
Persistent link: https://www.econbiz.de/10013044183
Closing the loopholes of downstream application of the Capper-Volstead exemption in the food system and pay-for-delay in pharmaceuticals is an important advance in US and EU antitrust norms. First, pay-for-delay conduct has been harmful for pharmaceuticals customers. After ten years of...
Persistent link: https://www.econbiz.de/10013021262
During its first three decades, the world lysine industry consisted of only three manufacturers protected by high technological barriers to entry. As the patented biotechnologies became more accessible, in the 1990s, seven other firms entered the market. Newer entrants tend to be experienced in...
Persistent link: https://www.econbiz.de/10012711034